SCHEMBL3774723

SCHEMBL3774723

CCCCCCCCCCC[C@@H](O)CC(N)=O

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 8/20 0.68
FFAR1 O14842 2/20 0.55
FFAR4 Q5NUL3 1/20 0.55
NFKB1 P19838 1/20 0.48
SPHK1 Q9NYA1 1/20 0.45
FAAH O00519 1/20 0.45
PSMD14 O00487 2/20 0.44
PLA2G1B P04054 2/20 0.44
MMP2 P08253 2/20 0.44
ATG4B Q9Y4P1 2/20 0.44
HSP90AA1 P07900 1/20 0.44
RAD52 P43351 1/20 0.44
TRPV1 Q8NER1 1/20 0.44
MAPT P10636 1/20 0.44
LCK P06239 1/20 0.44
PPARD Q03181 1/20 0.44
ZDHHC20 Q5W0Z9 1/20 0.44
ZDHHC2 Q9UIJ5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800461 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL6802390 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL8584469 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL6802183 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL8171086 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL10704633 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL8177703 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL8179521 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL8171084 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1
SCHEMBL8178632 1.00 GPR84 (0.68) GPR84FFAR1FFAR4NFKB1SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040743-A2 VACCINES FOR MALARIA GlaxoSmithKline Biologicals S.A. (BE) 2009-04-01 EP claimed
WO-2008009652-A2 VACCINES FOR MALARIA GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2008-01-24 WO claimed
WO-2023187366-A1 IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION OF INFLUENZA A OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-10-05 WO disclosed
EP-3535292-A1 FUSION POLYPEPTIDES DERIVED FROM STAPHYLOCOCCUS AUREUS ANTIGENS Oxford University Innovation Limited (GB) 2019-09-11 EP disclosed
EP-3535281-A1 FUSION POLYPEPTIDES Oxford University Innovation Limited (GB) 2019-09-11 EP disclosed
EP-3504235-A1 IMMUNOGENIC COMPOSITION Oxford University Innovation Limited (GB) 2019-07-03 EP disclosed
EP-3458087-A1 VACCINES Oxford University Innovation Limited (GB) 2019-03-27 EP disclosed
WO-2018037246-A1 IMMUNOGENIC COMPOSITION OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2018-03-01 WO disclosed
WO-2017199038-A1 VACCINES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2017-11-23 WO disclosed
WO-2010086617-A2 TREATMENT THE SECRETARY OF STATE FOR DEFENCE (GB) 2010-08-05 WO disclosed
EP-1870468-A2 LPS with reduced toxicity from genetically modified gram negative bacteria STAAT DER NEDERLANDEN VERTEGENWOORDIGD DOOR DE MINISTER VAN WELZIJN, VOLKSGEZONDHEID EN CULTUUR (NL) 2007-12-26 EP disclosed
WO-2007015167-A2 REDUCING INTERFERENCE BETWEEN OIL-CONTAINING ADJUVANTS AND SURFACTANT-CONTAINING ANTIGENS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-02-08 WO disclosed